The Company focuses on the emerging field of proteomics, which involves establishing the relationship between protein function and particular diseases by identifying disease-specific proteins. Myriad employs a variety of proprietary proteomic technologies to discover important disease genes and to understand the role these genes and their related proteins play in the onset and progression of disease. Using proprietary technologies, the Company identified 22 drug targets to date. Myriad delivered 13 of these drug targets to its strategic partners based on its discovery of genes involved in breast cancer, brain cancer, prostate cancer, heart disease, dementia and other disorders. MYGN operates a genetic predisposition testing lab and develops products to prevent or treat the diseases associated with these genes.
Revenues reflect increased research revenue from strategic alliances.
Lower loss benefitted from increased interest income. All Rights Reserved. Privacy Policy - Terms of Service Company information Copyright Market Guide . Some event data provided by StreetEvents . Data and information is provided for informational purposes only, and is not intended for trading purposes.